Capital Markets Day

Adriaan Moelker, CEO BRAIN Biotech AG, presents BRAIN Biotech´s strategy and priorities at the Capital Markets Day 2024.

Alexander Pelzer, VP Head of Research & Development at BRAIN Biotech Zwingenberg and Andrew Ellis, VP Fermentation & Technology at Biocatalysts Ltd. talk about the new shared technology platform #BRAINBiocatalysts. Through this platform, the BRAIN Biotech Group offers contract research and contract manufacturing for industrial enzymes.

Daren Bryce, Vice President Food & Pharmaceuticals at Biocatalysts Ltd, talks about the enzyme company's focus on high-value markets in the food and life sciences sectors and its application expertise in areas such as dairy, bakery, starch processing, fruit juice and wine production.

Dr Esther Gabor, Director, Head of Microbial Strain Development, speaking at BRAIN Biotech's Capital Markets Day 2024 about biotechnology as an enabler for more sustainable industrial production. She gives examples and talks about BRAIN Biotech's more than 750 microbial strains for use in the food and animal feed industries and beyond.

Michael Schneiders, CFO of BRAIN Biotech AG, talks about the company's vision to build a respected global top 10 enzyme company.